Acarix will publish its first quarter results on Tuesday 14 May 2024 at 08.00 am (CEST). A live webcast will be held at 15.00 (CEST) the same day, where CEO Aamir Mahmood and CFO Christian Lindholm will present the report. The presentation ends with a Q&A together with Redeye's analysts, where you can ask the company questions via the form on the live page.

The webcast will be available at https://www.redeye.se/events/995786/live-q-acarix-5

The presentation will be available at https://www.acarix.com/for-investors/investor-presentations 
after the webcast.

For more information contact:
Jennifer Anderson, Head of Marketing & Communications, phone +1 720 471 4625, email jennifer.anderson@acarix.com 

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

Attachments
Invitation to presentation of Acarix´s first quarter report

© Modular Finance, source Nordic Press Releases